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Open access under CC BY license.SUMMARYWe show that BRAFV600E initiates an alternative pathway to colorectal cancer (CRC), which progresses
through a hyperplasia/adenoma/carcinoma sequence. This pathway underlies significant subsets of CRCs
with distinctive pathomorphologic/genetic/epidemiologic/clinical characteristics. Genetic and functional an-
alyses in mice revealed a series of stage-specific molecular alterations driving different phases of tumor evo-
lution and uncoveredmechanisms underlying this stage specificity.We further demonstrate dose-dependent
effects of oncogenic signaling, with physiologic BrafV600E expression being sufficient for hyperplasia induc-
tion, but later stage intensified Mapk-signaling driving both tumor progression and activation of intrinsic tu-
mor suppression. Such phenomena explain, for example, the inability of p53 to restrain tumor initiation aswell
as its importance in invasiveness control, and the late stage specificity of its somatic mutation. Finally, sys-
tematic drug screening revealed sensitivity of this CRC subtype to targeted therapeutics, including Mek or
combinatorial PI3K/Braf inhibition.INTRODUCTION
Colorectal cancer (CRC) initiation and progression is driven by a
stepwise accumulation of genetic alterations (Fearon, 2011).Significance
Dissecting the molecular pathways to colorectal cancer is ess
ification of this genetically heterogeneous disease. Here, we
tumorigenesis, which differs in molecular, morphologic, epi
induced pathway. Our studies describe key aspects of mole
the stage at which they occur, and mechanisms underlying the
pharmacologic profiling revealed therapeutic opportunities for
common malignancy in the Western world. The BRAFmutant
cancers. Our studies provide pathogenic insights and provideThere is however considerable genetic heterogeneity, and tumor
subtypes evolve through different pathways. In the ‘‘classic’’
progression model, inactivation of the adenomatous polyposis
coli (APC) gene is an early initiating event, followed by additionalential to improve clinical classification and therapeutic strat-
provide evidence for a BRAF-initiated pathway to intestinal
demiologic, and clinical aspects from the ‘‘classic’’ APC-
cular tumor evolution, including tumor-driving alterations,
ir stage specificity. This knowledge together with systematic
this tumor subentity. Colorectal cancer is the second most
subset alone has a higher incidence than many other human
animal models for genetic/preclinical research.
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Figure 1. A Mouse Model of BrafV600E-Induced Intestinal Pathology
(A–D) Knockin strategy of theBrafV637E allele. Wild-typemouseBraf locus. Lha/Rha, left and right homology arms (A). TargetedBraf-locus (B). The Lox-STOP-Lox
cassette has an Engrailed-2 splice acceptor and 4 SV40 polyadenylation sites. It is flanked by Sleeping Beauty inverted terminal repeats permitting SB trans-
posase-dependent V637E activation, a feature not exploited in this study. Southern blot confirming correct targeting (C). F1 males were mated to Rosa26-FlpE
females to remove the FRT flanked puromycin resistance cassette (PuDTK), producing offspring with the BRAFLSL-V637E conditional allele (D).
(E) Villin-Cre-induced recombination of the STOP cassette inBrafLSL-V637E/+mice. Br, brain; H, heart; Sk, skin; T, testis; B, bladder; SV, seminal vesicle; S, spleen;
Li, liver; L, lung; M, muscle; K, kidney; E, esophagus; P, pancreas; F, forestomach; G, glandular stomach; D, duodenum; J, jejunum; I, ileum; C, coecum; Co,
colon; R, rectum.
(F–P) Pronounced generalized intestinal hyperplasia in Vil-Cre;BrafLSL-V637E/+ mice. Length of the small (SI) and large intestine (LI) in Vil-Cre;BrafLSL-V637E/+ mice
and BrafLSL-V637E/+ control animals (F). Error bars, SEM; n > 15 per group; *p < 0.05; **p < 0.001 by t test. Thickening and elongation of intestines in Vil-Cre;
BrafLSL-V637E/+ mice (G–P). Representative macroscopic (G/H), microscopic (I/J/M/N), and endoscopic (K/L/O/P) images of SI and LI from BrafLSL-V637E/+ controls
and Vil-Cre;BrafLSL-V637E/+ mice. Scale bars, 50 mm.
(legend continued on next page)
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Braf-Induced Intestinal Tumorigenesisalterations, such as KRAS and TP53 mutations (Fearon and
Vogelstein, 1990; Fearon, 2011). These classic tumors are
more often located in the distal colon and rectum and genetically
they frequently have chromosomal instability (CIN). In this ade-
noma-carcinoma sequence, adenomatous polyps are the
neoplastic precursor lesions of adenocarcinoma (Fearon, 2011).
Another type of polyp, the serrated polyp (formerly hyper-
plastic polyp) has long been considered to have no potential
for neoplastic progression. This concept was challenged by
the observation of cancers developing in patients with hyper-
plastic polyposis syndrome (Torlakovic and Snover, 1996) or in
sporadically occurring hyperplastic polyps (Torlakovic et al.,
2003). These studies recognized that lesions classified until
then as hyperplastic polyps represent in fact several subentities,
some of which are precancerous. Since then, numerous reports
have confirmed and extended these findings and conclusions
(for recent reviews see Noffsinger, 2009; Rex et al., 2012; Bet-
tington et al., 2013), and consequently hyperplastic polyps
have been renamed as serrated polyps. The latest World Health
Organization classification distinguishes three categories of
serrated polyps: hyperplastic polyps (HPs), sessile serrated
adenomas (SSAs), and traditional serrated adenomas (TSAs;
Snover et al., 2010). The major histologic feature of all serrated
polyps is the saw-toothed (serrated) infolding of the crypt
epithelium.
HPs are characterized by an expanded proliferation zone, but
do not have architectural changes or dysplasia. They account for
at least 80%–90%of serrated polyps and can be found in 20%of
adults in Western populations. Ninety percent of HPs are small
(<0.5 cm) lesions in the rectosigmoid and have little potential
for malignant progression. However, large left-sided HPs
(>0.5 cm) and right-sided HPs of any size have been associated
with increased cancer risk and their removal is nowbeing recom-
mended (Rex et al., 2012).
SSAs resemble HPs, but can be distinguished pathologically
by their abnormal architectural features, including dilated and
branched crypts. Increased proliferation can be observed, but
typically there is no or only minimal dysplasia. TSAs are charac-
terized by a tubulovillous architecture and eosinophilic epithe-
lium with serration and uniform cytologic atypia (dysplasia).
Both SSAs and TSAs have a significant risk for malignant trans-
formation and their removal is therefore recommended (Rex
et al., 2012).
It has been estimated that up to 30% of colorectal cancers
evolve from these precursor lesions through a ‘‘serrated
pathway’’ (Rex et al., 2012). Serrated cancers are considered
to differ not only morphologically, but also in their genetic
characteristics from ‘‘classic’’ tumors arising through the ade-
noma-carcinoma sequence (Noffsinger, 2009; Rex et al., 2012;
Bettington et al., 2013). Serrated polyps predominantly have
mutations in either BRAF or KRAS but less frequently in APC.
They typically lack CIN but often exhibit high level microsatellite
instability (MSI-H) and extensive DNA methylation of CpG
islands (CIMP-H). Based on these genetic alterations, Jass pro-(Q–T) Serrated hyperplasia in Vil-Cre;BrafLSL-V637E/+mice. Microvesicular hyperpl
serrated hyperplasia (Q and R). Goblet cell-rich hyperplasia in the large intestine w
cells in the large intestine (S and T). Scale bars, 50 mm.
See also Figure S1.posed that most serrated tumors can be classified into three
major subtypes: (1) KRAS mutant, CIMP-Low, MSS/MSI-Low;
(2) BRAF mutant, CIMP-H, MSI-H; and (3) BRAF mutant,
CIMP-Low, MSS/MSI-Low (Jass, 2007).
After the first reports of BRAF mutations in colorectal malig-
nancy (Davies et al., 2002; Rajagopalan et al., 2002), it has
soon been recognized that BRAF alterations are strongly associ-
ated with right-sided sessile cancers and its serrated precursor
lesions HPs and serrated adenomas (Chan et al., 2003; Yang
et al., 2004; Kambara et al., 2004; Spring et al., 2006). The
most frequent somatic alteration in BRAF is a point mutation
(T1799A encoding BRAFV600E), which results in a several hun-
dred-fold increased activity of the protein’s kinase domain.
This causes sustained activation of the MEK1/2 / ERK1/2
mitogen-activated kinase (MAPK) signaling cascade (Davies
et al., 2002), a pathway that controls a wide range of physiologic
and tumor-promoting processes, including self-renewal, prolif-
eration, senescence, apoptosis, invasion, and metastasis. To
study the role of BRAFV600E in intestinal tumorigenesis, we devel-
oped conditional BrafV637E knockin mice, in which mutant Braf
can be expressed in a tissue-specific manner from its endoge-
nous locus.
RESULTS
BRAFV600E Initiates a Serrated Pathway to Intestinal
Tumorigenesis
To examine the effect of BrafV600E in the intestine, we created a
Braf knockin allele, which can be activated by Cre, leading to the
production of the V637E mutant Braf protein. BrafV637E in mouse
exon 18 is at the orthologous position of the human BRAFV600E
mutation affecting exon 15. In the absence of Cre, a Lox-Stop-
Lox cassette located in intron 17 prevents expression of the
mutant allele (Figures 1A–1D). To direct mutant Braf expression
to the intestine, we used Villin-Cre (Vil-Cre) mice in which Cre is
broadly expressed in epithelia of the small and large intestine
(Madison et al., 2002). In Vil-Cre;BrafLSL-V637E/+ mice the stop
cassette at the Braf locus is excised specifically in the intestine
but not in other organs (Figure 1E). The murine Braf LSL-V637E
allele is a knockin allele and is thus expressed from the endoge-
nous Braf locus at physiologic levels.
All Vil-Cre;Braf LSL-V637E/+ animals developed lifelong persis-
tent generalized crypt hyperplasia affecting nearly every crypt,
leading to significantly elongated and thickened small and large
intestines (Figures 1F–1P; Figure S1A available online). Endo-
scopically and histologically, villi in the small intestine (SI) had
a thickened and deformed appearance and were often branched
(Figures 1I–1L). Changes in the large intestine (LI) included crypt
hyperplasia and mucosal protrusions resembling villous struc-
tures that replaced the normal crypt pattern (Figures 1M–1P).
This generalized hyperplasia was characterized by focal serrated
epithelial formations, which had cytomorphologic features of
human microvesicular or goblet cell-rich hyperplastic (serrated)
polyps (Figures 1Q–1T and S1B). Both types were present inasia in the SI showing crypt elongation and serrated epithelium. mSH, murine
ith crypt elongation, sparsely serrated epithelium and large numbers of goblet
Cancer Cell 24, 15–29, July 8, 2013 ª2013 Elsevier Inc. 17
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Braf-Induced Intestinal Tumorigenesisthe LI, whereas microvesicular hyperplasia was predominant in
the SI. Because of this resemblance to human serrated hyperpla-
sia (Figure S1B), we refer to the histology in the mouse as murine
serrated hyperplasia (mSH).
Like in human serrated hyperplastic polyps, there was a mild
increase in the number of proliferating cells in mSH as compared
to wild-type mucosa (Figures S1C and S1D). Ki67-positive
cells were present in the mid and/or upper crypt in Vil-Cre;
Braf LSL-V637E/+ intestines but were restricted to the lower crypt
in wild-type intestines (Figure S1C). Hyperproliferation seems
to be the underlying mechanism of the hyperplastic changes
because apoptosis was not reduced in Vil-Cre;BrafLSL-V637E/+
intestines as compared to wild-type mucosa (Figures S1E and
S1F). We also intercrossed LSL-BrafV600E mice with Lgr5-
EGFP-IRES-CreERT2 knockin mice. Tamoxifen-inducible Lgr5-
Cre allowed stochastic activation of mutant Braf in a part of
the intestinal stem cells, thereby inducing hyperplastic polyps
in nonhyperplastic surrounding mucosa (Figure S1G). BRAF
mutations have been observed in human serrated polyps occur-
ring sporadically or in serrated polyposis syndrome andwe show
here that BRAFV600E is indeed the underlying initiating event that
is sufficient to induce lifelong sustained hyperplasia.
BRAFV600E Induced Serrated Tumorigenesis Progresses
through a Hyperplasia/Adenoma/Carcinoma Sequence
To investigate whether mSH progresses to dysplasia, we aged
Vil-Cre;BrafLSL-V637E/+mice up to 18 months and sacrificed
them at various time points. Hyperplasia to dysplasia progres-
sion was often observed at a young age (2–3 months), at which
time some animals already developed macroscopic tumors
(>2 mm) with dysplasia. At 10 months, virtually all mice had
such dysplastic lesions, often large numbers (Figure 2A). Histo-
logically, BrafV637E-induced dysplastic lesions had features of
human traditional serrated adenomas (TSAs), including crypt
elongation and a serrated eosinophilic adenomatous epithelium
(Figures 2B–2E and S1B). Although both TSAs and SSAs are
associated with mutant BRAF in humans, we did not observe
SSA in our model. A possible reason is that mouse tumors
were predominantly in the SI (only five of 95 tumors were in the
large intestine), where the specific morphologic features of
human colonic SSAs might not develop. To avoid misleading
nomenclature by drawing inadequate morphologic parallels
between murine SI lesions and human LI tumors, we refer to
dysplastic lesions as ‘‘murine serrated adenoma with dysplasia’’
(mSA) or more specifically as mSA with low-grade dysplasia
(mSA-LGD) or high-grade dysplasia (mSA-HGD).
Macroscopically, BrafV637E-induced neoplasia resembled
human BRAF mutant colonic tumors, which frequently show a
nonpolypoid sessile growth pattern (Figure S2A). Proliferation
rates were increased on average 2.4-fold in mSA-LGD and
9.1-fold in mSA-HGD as compared to hyperplasia (Figures
S2B–2D). Like human BRAF mutant tumors, mouse mSAs
frequently showed abundant mucin production and stained
positive for Alcian blue (Figure S2E).
In a subset of mice (n = 5) dysplasia progressed to invasive
carcinomas: 8.3% (1/12) of Vil-Cre;BrafLSL-V637E/+ mice younger
than 10 months and 13.8% (4/29) of mice older 10 months had
cancers (Figure 2A). Two of these cancers were low-grade
tumors (well and moderately differentiated), and three were18 Cancer Cell 24, 15–29, July 8, 2013 ª2013 Elsevier Inc.high-grade cancers (poorly or undifferentiated; glandular struc-
tures in less than 50% of the tumor). Examples are shown in Fig-
ures 2F–2I. Across a larger set of BrafV637E-induced cancers in
p53 or p16 mutant backgrounds (Table S1 and detailed below),
we found that 30% of tumors were high grade. Collectively these
results describe a mouse model of serrated intestinal cancer,
which provides functional evidence for the key role of mutant
Braf in tumor initiation.
BrafV637E-Induced Murine Intestinal Tumors
Are Frequently Microsatellite-Unstable
High level microsatellite instability (MSI-H) occurs in 50% of hu-
man BRAF mutant cancers (Rajagopalan et al., 2002). It is how-
ever not understood at which stage MSI develops and whether
BRAF mutations are cause or consequence of MSI. To address
this question, we assessed the MSI status in BrafV637E-induced
serrated hyperplasia and neoplasia as well as in Msh2/ and
Apcmin control tumors. A panel of eight microsatellite repeats
was used for MSI typing (Figure 2J; Supplemental Experimental
Procedures). We found that all BrafV637E-induced hyperplastic
polyps (13/13) were microsatellite stable (MSS) or MSI-low
(MSI-L). Contrarily, 39.4% (13/33) of BrafV637E-induced mSAs
and carcinomas were MSI-H and only 6% (2/32) were MSS (Fig-
ure 2J). MSI-H was observed at similar frequencies in mSAs
(10/25; 40%) and carcinomas (3/8; 37.5%). Apcmin-induced
adenomas were all (9/9; 100%) MSS or MSI-L. The lack of
MSI-H in mSH, but its presence in all subsequent stages of
tumorigenesis (mSA-LGD, mSA-HGD and carcinoma) suggests
its early development during BrafV637E-initiated transformation.
P53 Tumor Suppression Inhibits Invasion and
Metastasis but Does Not Affect Tumor Initiation in
BrafV637E-Induced Tumorigenesis
The long latency and low penetrance of cancer develop-
ment might be explained by the ability of constitutive MAPK
signaling to activate anti-oncogenic programs, most notably
the p16INK4a/Rb and p19ARF/p53 pathways (Palmero et al.,
1998; Lin et al., 1998).
To investigate the role of p53 in BrafV637E-induced intestinal
tumorigenesis, we used p53LSL-R172H/+ knockinmice, expressing
the equivalent of the dominant-negative human TP53R175H
conditionally (Olive et al., 2004). We intercrossed them with Vil-
Cre;BrafLSL-V637E/+ mice, aged the different double- and triple-
transgenic cohorts, and monitored mice for tumor development
(Figure 3A). We found that the average number of mSAs
per mouse was similar in Vil-Cre;BrafLSL-V637E/+ and Vil-Cre;
BrafLSL-V637E/+;p53LSL-R172H/+ animals (2.3 and 1.8, respectively;
Figure 3B; Table S2). Likewise, the proportion of mice devel-
oping mSAs did not differ between groups (82.9% and 82.8%,
respectively, Table S2), suggesting that the p53 pathway does
not restrain dysplasia initiation.
In sharp contrast, invasive cancers were found considerably
more frequently in Vil-Cre;BrafV637E/+;p53LSL-R172H/+ mice (Fig-
ure 3B; Table S3). Fifty-six percent of Vil-Cre;BrafLSL-V637E/+;
p53LSL-R172H/+ animals at an age of 10–20 months had
carcinomas, as compared to 13.8% of mice in the Vil-Cre;
BrafLSL-V637E/+ cohort (p = 0.002, c2 test). The average num-
ber of cancers was 5.2 times higher in the Vil-Cre;
BrafLSL-V637E/+;p53LSL-R172H/+ cohort (p = 0.007; Mann-Whitney
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Figure 2. Intestinal Neoplasia Development in Vil-Cre;BrafLSL-V637E/+Mice
(A) Overview of intestinal neoplasia development in Vil-Cre;BrafLSL-V637E/+mice. Each circle represents one mouse. Green circles, mice without macroscopic
neoplasia. Blue circles, mice with macroscopic serrated adenomas mSAs (defined as tumors > 2 mmwith dysplasia, identified at necropsy). The mSA number is
indicated on the y axis. Animals represented by red circles had mSA(s) plus at least one carcinoma. Microscopic dysplasia is not shown.
(B–I) Serrated dysplasia and adenocarcinoma in Vil-Cre;BrafLSL-V637E/+mice. Scale bars, 50 mm. Murine serrated adenoma with low-grade dysplasia (mSA-LGD)
in the small intestine showing tubulovillous architecture and serrated, eosinophilic adenomatous epithelium (B and C). Murine serrated adenomawith high-grade
dysplasia (mSA-HGD), showing tubulovillous architecture, sparse serration, and a high degree of atypia (D and E). Low-grade adenocarcinoma, showing pre-
dominant tubular differentiation (F and G). High-grade adenocarcinoma with remnants of tubular structures in the upper left part, but predominant loss of tubular
differentiation in other areas (H and I).
(J) Microsatellite instability in BrafV637E-induced hyperplasia/neoplasia as well as Apc- andMsh2mutant tumors. Eight markers were used for MSI-typing (see the
Supplemental Experimental Procedures). Each column represents one sample. Samples were defined as microsatellite stable (MSS; all eight markers stable),
MSI-Low (MSI-L; one or more, but < 40% of markers unstable) or MSI-H (R40% of markers unstable).
See also Figure S2 and Table S1.
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Braf-Induced Intestinal Tumorigenesisrank sum test). Some animals had more than one synchronous
cancer and 25% (3/12) of mice with cancer had metastases to
local lymph nodes, pancreas, or lungs (Figures 3C and 3D). All
together, these data show that p53 does not affect early stages
of BrafV637E-induced tumorigenesis but plays an important role
in invasiveness control.Activation of p53 Tumor Suppression during Advanced,
but Not Early Tumorigenesis
We next examined at which stage of tumorigenesis the p53
pathway becomes activated (Figures 3E–3N). We performed
immunohistochemistry for p53 and its target gene p21 in
wild-type as well as Braf mutant hyperplasia and neoplasia.Cancer Cell 24, 15–29, July 8, 2013 ª2013 Elsevier Inc. 19
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Braf-Induced Intestinal TumorigenesisImmunoreactivity for p53 was negative in all wild-type intestines
(n = 21), all BrafV637E-induced mSHs (n = 43), and most mSAs-
LGD (Figures 3F–3H and 3N). Only 5/37 mSAs-LGD were p53-
positive (example in Figure 3I). We detected however marked
p53 expression in 97% (28/29) of mSAs-HGD (Figures 3L
and 3N). There was a strong concordance of p53 and p21 immu-
noreactivity in all samples. Similar to p53, p21 IHC was negative
in all wild-type intestines (n = 21), all BrafV637E-induced mSHs
(n = 15), and most (10/11) mSAs-LGD but was present in the
majority (8/9; 89%) of mSAs-HGD (Figures 3G, 3J, 3M, and 3N).
These data suggest selective activation of p53 tumor suppres-
sion during advanced but not early stages of tumor evolution.
To investigate the mechanism of p53 activation, we first
stained for the DNA damage marker gH2AX. Oncogene-
induced DNA damage can activate p53 via ARF-independent
pathways (Sherr and McCormick, 2002). All mSHs (n = 20) or
mSAs-LGD (n = 12) were gH2AX-negative (Figure 3K), and
only three of 17 mSAs-HGD (all p53/p21-positive) showed evi-
dence for activation of the DNA damage response. In contrast,
p19Arf expression increased substantially during tumor pro-
gression: average normalized p19Arf mRNA levels were similar
in BrafV637E-induced mSHs (0.7) and wild-type mucosa (1.0),
but were increased 9.9-, 32.3-, and 39.4-fold in mSAs-LGD,
mSAs-HGD, and carcinomas, respectively (Figure 3E). We
conclude that p53 is activated mainly via p19Arf in advanced
BrafV637E-iduced tumorigenesis, explaining its late stage spe-
cific function.
Selective Pressure for p53 Inactivation Develops
at Advanced Stages of Tumor Evolution
To examine whether p53mutations occur spontaneously during
BrafV637E-induced intestinal tumorigenesis, we next sequenced
p53 in Braf mutant tumors. Whereas mSAs (n = 17) did not
have p53 mutations, we identified a missense mutation
(S152R; equivalent of human T155A) in one of the two carci-
nomas. S152R leads to stabilization of nonfunctional p53, as
evidenced by loss of p21 expression in cancer cells (Figures
3O–3Q). In the second cancer, p53 expression was lost whereas
the surrounding dysplasia, which gave rise to the cancer, was
p53-positive (Figures 3R and 3S). These results suggest late
stage specific selective pressure to inactivate p53, further
supporting the importance of p53 for invasiveness control.Figure 3. P53 Is Activated Late during BrafV637E-Induced Intestinal Tum
(A) Intestinal tumor type, number, and latency in Vil-Cre;BrafLSL-V637E/+;p53LSL-R
macroscopic neoplasia. Blue circles, mice with macroscopic serrated adenomas
(B) Average adenoma and carcinoma number in Vil-Cre;BrafLSL-V637E/+;p53LSL-R
Whitney rank sum test. Error bars, SEM.
(C and D) Lung metastasis of intestinal cancer in a Vil-Cre;BrafLSL-V637E/+;p53LSL-
bars, 50 mm.
(E) Expression of p19Arf in small intestinal samples with the indicated genotypes
expression. mSH, murine serrated hyperplasia; mSA-LGD, murine serrated adeno
grade dysplasia. Error bars, SEM.
(F–M) p53, p21, or gH2AX staining in SI samples from Vil-Cre;BrafLSL-V637E/+ mi
dysplasia (I–K), high-grade dysplasia (L and M). T, transition hyperplasia/dysplas
(N) Frequency of positive staining for p53 and p21 in indicated sample types from
(O–S) p53 and p21 staining in two carcinomas from Vil-Cre;BrafLSL-V637E/+ mice.
negative for p21 (Q and R). In a second cancer there was loss of p53 expression
carcinoma. Scale bars, 50 mm.
See also Tables S2 and S3.Inactivation of p16 Promotes Advanced Phases
of BrafV637E-Induced Intestinal Tumorigenesis
To examine the role of p16Ink4a, we first analyzed p16Ink4a
expression in Braf mutant healthy and neoplastic intestines
(Figure 4A). Whereas p16Ink4a expression was similar in Braf
mutant mSH and WT mucosa, there was a marked upregulation
of p16Ink4a expression in Braf mutant neoplasia. This effect was
less pronounced in mSAs-LGD than in mSAs-HGD, in which
p16Ink4a was induced on average 100-fold (Figure 4A). Thus,
similarly to BrafV637E-induced Arf/p53 activation, substantial
p16Ink4a activation is only triggered at advanced stages of tumor-
igenesis. This is consistent with observations in humans, where
p16 was upregulated in BRAF mutant premalignant lesions
(SSAs and TSAs) but not in hyperplasia (Kriegl et al., 2011).
To investigate whether p16Ink4a inactivation occurs spontane-
ously in BrafV637E-induced tumors, we performed comparative
genomic hybridization, sequencing, and methylation analysis
of the cdkn2a locus. We did not identify Cdkn2a mutations or
copy number alterations in any of the 12 TSAs and eight carci-
nomas analyzed (data not shown). In a subset of BrafV637E-
induced mSAs-HGD and carcinomas, however, we found
partial CpG island methylation in the p16Ink4a (but not p19Arf)
promoter (Figure S3), similar to observations in humans (Kriegl
et al., 2011).
To study the effect of p16Ink4a inactivation in vivo, we used
p16Ink4a* mice, which have a point mutation that is silent in the
p19Arf reading frame but introduces a stop codon in p16Ink4a
(Krimpenfort et al., 2001). Vil-Cre;BrafLSL-V637E/+ mice with
heterozygous or homozygous mutation of p16Ink4a (Vil-Cre;
BrafLSL-V637E/+;p16Ink4a*) were aged and sacrificed at different
time points to assess tumor incidence and latency (Figure 4B).
We observed 1.3-fold increased numbers of mSAs in Vil-Cre;
BrafLSL-V637E/+;p16Ink4a* animals as compared to Vil-Cre;
BrafLSL-V637E/+ mice, but this was statistically not significant
(Figure 4C; Table S4). In contrast, carcinoma development was
significantly increased in Vil-Cre;BrafLSL-V637E/+;p16Ink4* mice,
which had on average 6.4 times as many cancers as Vil-Cre;
BrafLSL-V637E/+;p16Ink4a+/+ mice (p < 0.001; Figure 4C; Table
S5). Many of the mice developed multiple synchronous carci-
nomas and, in some animals (3/24), these tumors were metasta-
tic. All together, these results show that Arf/p53 and p16 exert
independent critical tumor-suppressive effects, which aremainlyorigenesis and Plays an Important Role in Invasiveness Control
172H/+ mice. Each circle represents one mouse. Green circles, mice without
mSAs (defined as tumors > 2 mm with dysplasia, identified at necropsy).
172H/+ mice as compared to Vil-Cre;BrafLSL-V637E/+ animals. **p < 0.01, Mann-
R172H/+ mouse stains positive for the enterocytes-specific marker CK20. Scale
and histology; n = 55 (total); error bars, SEM p19Arf was normalized to Actb
mawith low-grade dypslasia; mSA-HGD, murine serrated adenoma with high-
ce: hyperplasia (F and G), low-grade dysplasia (H), area with hyperplasia and
ia; Scale bars, 50 mm for micrographs, 20 mm for insets.
Vil-Cre;BrafV637E/+ mice. N = 110 (for p53); n = 35 (for p21).
A cancer with spontaneous p53 mutation (S152R) stains positive for p53 but
in invading cancer cells (arrows) but not in the area of dysplasia (R and S). Ca,
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Figure 4. TheRole of p16-Dependent Tumor
Suppression in BrafV637E-Induced Intestinal
Carcinogenesis
(A) p16Ink4a expression (qRT-PCR; normalized to
Gapdh) in SI samples with the indicated genotypes
and histology; n = 55 (total); Error bars, SEM.
(B) Intestinal tumor type, number, and latency
in Vil-Cre;BrafLSL-V637E/+;p16*/+ and Vil-Cre;
BrafLSL-V637E/+;p16*/* mice. Each circle/triangle
represents one mouse. Green circles/triangles,
mice without macroscopic neoplasia. Blue circles/
triangles, mice with macroscopic serrated ade-
nomas mSAs (defined as tumors > 2 mm with
dysplasia, identified at necropsy). Note that some
mice had multiple independent cancers.
(C) Average mSA and carcinoma number in Vil-
Cre;BrafLSL-V637E/+;p16* mice as compared to Vil-
Cre;BrafLSL-V637E/+ animals. p16* indicates all p16
mutant mice (hetero- and homozygous); *p <
0.001, Mann-Whitney rank sum test. Error bars,
SEM.
See also Figure S3 and Tables S4 and S5.
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Braf-Induced Intestinal Tumorigenesisoperative at advanced stages of BrafV637E-induced intestinal
tumorigenesis.
Intensification ofMapKinase Signaling during Dysplasia
Progression
Because Braf-induced Mapk signaling does not seem to engage
intrinsic tumor suppression in early tumorigenesis, we next as-
sessed the MAPK pathway activity at different stages of tumor
evolution. Unexpectedly, phospho-p42/p44 MAPK (pErk) pro-
tein levels were only slightly increased in BrafV637E-induced
mSH as compared to wild-type mucosa but were highly induced
in mSAs and carcinomas (Figure 5A). Immunohistochemistry
revealed that in wild-type mucosa and BrafV637E-induced mSH,
pErk reactivity was mostly confined to the lower parts of the
crypts (Figures 5B and 5C). In mSAs-LGD, few scattered
pERK-positive cells were occasionally additionally detected in
dysplastic areas (Figure 5D). mSAs-HGD and carcinomas, how-
ever, stained uniformly positive for pErk (Figures 5E–5G).
Compared to wild-type mucosa, the number of pERK-positive
cells per gland was increased 1.4-, 2.4-, and 6.6-fold in mSH,
mSAs-LGD, and mSAs-HGD, respectively (Figure S4A). To
assess the functional relevance of these observations, we exam-
ined expression of a panel of 15 Erk target genes (Pratilas et al.,
2009) using qRT-PCR (Figure 5H) or immunohistochemistry (Fig-
ure S4). The panel of markers includes a number of effectors of
Ras/Raf-induced transformation, such as the ETS family mem-
bers Etv4 and Etv5 or cMyc and Ccnd1, and genes involved in
the feedback regulation of Mek/Erk signaling, such as Dusp4,
Dusp6, Spry2, and Spry4. We found that the transcriptional
output of the Erk pathway was only slightly induced in22 Cancer Cell 24, 15–29, July 8, 2013 ª2013 Elsevier Inc.BrafV637E-dependent mSH and mSAs-
LGD (average fold-change across target
genes: 1.1 and 3.4, respectively) but
was strongly upregulated in mSAs-HGD
and carcinomas (average fold-change
across target genes: 13.0 and 12.6,
respectively). The extent of inductionvaried between markers and was highest for Fosl1 (60-fold
induction in BrafV637E-induced mSAs-HGD).
Wnt Pathway Activation during Dysplasia Progression
To examine the role of the Wnt pathway in BrafV637E-induced
tumorigenesis, we first analyzed the expression of ten different
Wnt target genes in a total of 78 samples (Figures 6A and S5).
We found that Wnt target gene expression was similar in wild-
type mucosa and BrafV637E-induced mSH but was upregulated
in a large number of BrafV637E-induced mSAs-HGD (and occa-
sionally in mSAs-LGD) to similar levels as in Apcmin-induced
tumors. Immunohistochemical staining of beta-catenin (Ctnnb1),
a key effector of Wnt pathway activation, was performed to
further confirm these observations. As in wild-type mucosa,
there was no evidence for nuclear b-catenin accumulation in
mSHs (n = 42) and themajority of mSAs-LGD (14/15). In contrast,
there was diffuse or focal nuclear b-catenin accumulation in
a substantial part of mSAs-HGD (8/14) and carcinomas (2/4)
(Figures 6B–6F).
To analyze the mechanisms of Wnt pathway activation, we
performed whole-exome sequencing of 20 Braf mutant tumors.
We identified a number of mutations in known Wnt pathway
genes (Table S6), including intracellular components of the Wnt
pathway (e.g., Apc, Ctnnb1, Gsk3b, and Axin2), Wnt receptors
(e.g., Lrp8 and Fzd9), or negative regulators of Wnt signaling
(e.g., Lrp1b and Lrp4). We then further analyzed the most
frequently altered genes (Apc, Ctnnb1, and Lrp1b) in another
46 tumors and found mutations in these three genes in 21/66
samples: Apc (n = 6), Ctnnb1 (n = 9), and Lrp1b (n = 6). Wnt
pathway mutations frequently occurred in high-grade dysplasia,
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micrographs, 20 mm for insets.
(H) Expression of Erk target genes (qRT-PCR;
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cated histology and genotypes. FC, fold-change
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bars, SEM.
See also Figure S4.
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Braf-Induced Intestinal Tumorigenesissuggesting an early requirement during tumorigenesis. Only
missense, nonsense, essential splice site mutations or frame-
shift-causing indels were observed (no silent mutations), sug-
gesting a strong enrichment for functionally relevant events.
For example, Apcmutations were mostly nonsense or frameshift
mutations, whereas Ctnnb1 mutations were recurrent activating
mutations at specific positions that have also been described in
humans (e.g., T141I). Missense mutations in Lrp1b, a negative
regulator ofWnt signaling, have been found earlier inBrafmutantCancer Cell 24,human melanoma (Nikolaev et al., 2012).
All together, these results provide strong
evidence for an important role of Wnt
pathway activation during early dysplasia
progression. It is worth noting that in
some tumors with strong Wnt target
gene expression, no mutations in Wnt
pathway genes were found, suggesting
additional unidentified mechanisms.
Large-Scale Drug Screening
Identifies Targetable Nodes in
Braf-Induced Tumorigenesis
To test the sensitivity of BrafLSL-V637E/+-
induced intestinal cancer cell lines to
Braf inhibition we performed short-term
proliferation assays. Overall, only minor
growth inhibition was observed for Braf
mutant mouse and human colorectal
cancer cell lines treated with 5 mM
PLX4720, a selective inhibitor of mutant
Braf (Figures 7A and 7B).
Braf inhibition was proposed to cause
feedback activation of the epidermal
growth factor receptor (EGFR) in human
BRAF mutant CRCs (Prahallad et al.,
2012). We therefore treated mouse and
human BRAF mutant cell lines with the
EGFR small molecule kinase inhibitor,Gefitinib, alone or in combination with PLX4720. As expected,
Gefitinib and PLX4720 synergized in-growth inhibition (Figures
7A and 7B). The murine intestinal cancer cell line MouseT1
(from a Vil-Cre;BrafLSL-V637E/+;p53LSL-R172H/+mouse), had similar
sensitivity to combinatorial PLX4720/Gefitinib treatment as
HT-29 (WiDr), one of the three human cell lines tested by
Prahallad and colleagues (Figures 7A and 7B; inhibition of pro-
liferation by 60%–70%). It seems, however, that the effective-
ness of PLX4720/Gefitinib varies considerably among human15–29, July 8, 2013 ª2013 Elsevier Inc. 23
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Braf-Induced Intestinal Tumorigenesiscancers: in three of five tested human cell lines the effects were
rather modest (growth inhibition by 25%–40%; Figure 7A and
data not shown). We next performed long-term (14 days)
clonogenic assays and again found that although PLX4720 and
Gefitinib synergized in-growth inhibition, most of the treated
cell lines retained variable levels of colony-forming capacity
(Figure 7C).
To identify alternative drugs with effectiveness across cell
lines, we performed high-throughput drug screening. We tested
a large set of compounds inhibiting a broad range of molecules,
pathways, and biologic processes (Figure 7B; Table S7). All
compounds were tested alone or in combination with PLX4720
and for each cell line we performed 100 different short-term
(6 day) sensitivity assays. These screens revealed several
treatment approaches that were highly effective (Figure 7B).
PD0325901, a Mek inhibitor, was the most effective single
compound across cell lines in the short-term assays (Figure 7B).
In the long-term clonogenic assay, it induced complete inhibition
of colony-forming capacity in five of six cell lines and partial inhi-
bition in the remaining line RKO (Figure 7C). The PI3K inhibitor
GDC0941was not effective as a single agent, but induced potent
inhibition in combination with PLX4720 across cell lines (Figures
7B and 7C).
Some other drug combinations strongly inhibited selected cell
lines, although they were not broadly effective across tumors.
For example, the combination of PLX4720 plus the kinase
inhibitor VX-680 was the most potent drug combination for the
treatment of RKO, a highly resistant cell line to most other drugs.
This shows the power of systematic drug screening to identify
patient-specific treatment approaches even for highly resistant
tumors. Another example is the combination of the Chk1/2 in-
hibitor AZD-7762 plus PLX4720, which was very effective in
MouseT1, HT-29, LS411N, and COLO-205 and could potentially
be a broadly effective alternative first-line or second-line
combination.24 Cancer Cell 24, 15–29, July 8, 2013 ª2013 Elsevier Inc.In Vivo Validation of Mek and Combinatorial Braf/PI3K
Inhibition
To study the effectiveness of broadly effective drug combina-
tions in vivo, we first transplanted mouse and human cell lines
subcutaneously (s.c.) into immunodeficient Nod Scid IL12R-
gamma null (NSG) mice and assessed their response to
PD0325901. Treatment was started 7–14 days after s.c. injection
of cells as soon as tumors were palpable. Animals were given
PD0325901 or vehicle by oral gavage for 13–15 days.
PD0325901 was highly effective, causing regression of tumors
from all tested cell lines (Figure 7D). Figures S6A and S6B
show that after 13–15 days of PD0325901 treatment there was
complete inhibition of ERK phosphorylation in surviving tumor
cells and that only very few scattered Ki67-positive cancer cells
could still be observed in the necrotic tumor mass.
We next performed orthotopic transplantation of mouse and
human Braf mutant cancer cell lines into the cecum of NSG
mice. Fourteen days later, treatment was started with either
vehicle or PD0325901. Mice were sacrificed after 17 days of
treatment. Figures S6C–S6E show that vehicle-treated mice
developed large tumors, which metastasized to local lymph
nodes and the peritoneum, causing hemorrhagic ascites. In
contrast, in the PD0325901-treated group, tumors were either
not detectable or small (maximum 0.01 cm3).
To examine the effect of PD0325901 on proliferation in endog-
enousBrafV637E-induced tumors,weperformed short-term treat-
ments (5 days) of Vil-Cre;BrafLSL-V637E/+ mice. We used animals
that were more than 1 year of age and were expected to have
tumors. Figures S6F and S6G show that Ki67 immunoreactivity
wasweak in themajority of dysplastic cells inPD0325901-treated
mice but was strong in tumors of vehicle-treated animals. All
together, these data show that Mek inhibition is effective in the
treatment of Braf-induced intestinal tumors in vivo.
To examine the effectiveness of combinatorial Braf/PI3K inhi-
bition in vivo we treated s.c. transplanted murine and human cell
Cancer Cell
Braf-Induced Intestinal Tumorigenesislines with a combination of PLX4720 and GDC0941 or vehicle.
Figures 7E, S6H, and S6I show that combined Braf/PI3K inhibi-
tion elicited potent growth inhibition in both models. Immunohis-
tochemical staining revealed that proliferation was substantially
inhibited in the PLX4720/GDC0941-treated group, with only few
Ki67-positive cells being detectable in regressed tumor masses
(Figure S6I). These data mirror the in vitro effectiveness of these
treatments in vivo.
DISCUSSION
CRC is the second most common cancer in the Western world
(Jemal et al., 2010). BRAF mutations occur in more than 10%
of cases and define a subset that has a higher incidence than
many other solid or hematopoietic tumor entities. Despite this
high incidence, the molecular evolution of the disease is poorly
understood. Since the discovery ofBRAFmutations in colorectal
cancer (Davies et al., 2002), a vast body of literature has been
published on the association of BRAF mutations with other
genetic and epigenetic events in CRC. However, the interpreta-
tion of these observations, their functional relevance, and the
sequence of events driving tumorigenesis remained largely
speculative. We established mouse models that recapitulate
human BRAFV600E-associated intestinal pathology, including
sustained hyperplasia, serrated adenomas and metastatic
carcinomas. They reflect themacroscopic appearance of human
BRAF mutant tumors (flat nonpolypoid neoplasia), their patho-
morphologic characteristics (serrated and mucinous appear-
ance), their genetic features (e.g., microsatellite instability), and
their response to targeted therapeutics. Using these models,
we dissected key aspects of the molecular evolution of
these tumors. Our findings suggest a progression model of
BrafV637E-induced carcinogenesis as summarized in Figure 8.
Engineered animal models that accurately recapitulate
the characteristics of human disease are powerful tools for
genetic and preclinical cancer research. Recently, AhCre;
BrafLSL-V600E/+ mice have been used to examine the effects of
mutant Braf in the intestine (Carragher et al., 2010), but intestinal
tumorigenesis was difficult to study due to early onset BrafV600E-
induced extraintestinal cancer development and lethality. This
might explain why some of the main conclusions of that study
are not supported by our data or by observations in human sam-
ples. For example, Braf-induced hyperplasia was described to
be transient in that model but is sustained in human BRAF
mutant hyperplastic polyps and in our model. Likewise, our
data as well as work performed on human samples (Fujita
et al., 2011; Yachida et al., 2009) refute that BrafV637E expression
induces generalized Wnt pathway activation in human intestinal
hyperplasia, as suggested in that study (Carragher et al., 2010).
Alterations in APC occur in 80% of human CRCs. Because
APC mutations are less frequent in the BRAF mutant CRC sub-
set, it was largely assumed that BRAFV600E-associated intestinal
tumorigenesis is Wnt-independent (Samowitz et al., 2007; Jass,
2007). However recent studies, which used b-catenin immuno-
histochemistry rather than mutation analysis as a measure of
Wnt pathway activation found nuclear b-catenin reactivity in a
large part of BRAF mutant advanced (but not early) human
adenomas and in carcinomas (Fujita et al., 2011; Yachida
et al., 2009). Our results in mice not only mirror this situationbut explain these apparent discrepancies and establish stage-
specific Wnt pathway activation as a hallmark of BrafV637E-
induced dysplasia progression. We found a large spectrum of
Wnt pathway genes mutated in our murine tumors, similarly to
human ‘‘hypermutated’’ tumors, as described recently by the
Cancer Genome Atlas research network (Muzni et al., 2012).
In humans, serrated colorectal cancers are associated with
either BRAF or KRAS mutations. A series of studies in Kras
mutant mouse models demonstrated Kras-initiated serrated
tumorigenesis (Janssen et al., 2002; Haigis et al., 2008;
Bennecke et al., 2010; Feng et al., 2011). The BrafV637E- and
KrasG12D-induced pathways differ however in several aspects.
First, BrafV637E seems to be a highly potent oncogene, inducing
cancers even on an otherwise wild-type background. The tumor
incidence in the BrafV637E-model is even higher than in trans-
genic lines expressing multiple KrasG12V copies (Janssen et al.,
2002). Second, while KrasG12D-induced serrated tumors do not
seem to require Wnt pathway activation (Bennecke et al.,
2010), we find evidence for Wnt signaling induction in a substan-
tial part of BrafV637E-induced high-grade tumors. Third, murine
and human intestinal tumors with KRAS mutations are mostly
MSI-stable or MSI-low (Noffsinger, 2009; Bennecke et al.,
2010), whereas BRAF mutant human tumors are frequently
MSI-high (Rajagopalan et al., 2002). This genetic feature is faith-
fully recapitulated in our model, which not only causally links
BrafV637E to MSI development, but also demonstrates its early
stage development. Finally, BRAF mutant human tumors
have—in contrast to KRASmutant serrated tumors—a predilec-
tion for proximal (right-sided) location and are more frequent in
females than in males (Spring et al., 2006). Collectively, these
data provide compelling evidence for the existence of different
pathways to serrated intestinal tumorigenesis.
Our studies revealed that p19Arf/p53 and p16Ink4A exert inde-
pendent critical tumor-suppressive effects. p16Ink4A inactivation
is a critical early event promoting neoplastic transformation in
some types of cancers, whereas in other tumor types it has
been described to be an intermediate or late event (Romagosa
et al., 2011). A recent study even showed that extrinsic signals
present in a emerging tumor induce local non-cell-autonomous
p16Ink4A expression (Burd et al., 2013). We found that experi-
mental p16Ink4A inactivation has only a mild effect on dysplasia
initiation, but substantially increases the incidence of cancers.
The lack of p16Ink4A tumor suppression during early stages
was surprising, given that p16Ink4A was believed to mediate an
early BRAFV600E-induced senescence program in nontrans-
formed enterocytes. BRAFV600E-induced senescence has been
extensively studied in cutaneous nevi, where it induces a near-
total block of proliferation (Michaloglou et al., 2005). Hyper-
plastic serrated intestinal polyps in humans and in our mouse
model differ however from nevi in that they are hyper- and not
hypoproliferative.
Another surprising finding was the role of p53 in Braf-depen-
dent intestinal tumorigenesis. p53 mutations were reported to
be relatively rare in human serrated cancers. Although these
studies were based on low sample numbers, many authors
assumed that p53 alterations do not play a role in the ‘‘serrated
route’’ of intestinal tumorigenesis (Jass, 2007), thereby contrast-
ing classic colorectal cancer development. Our data clearly
demonstrate that this assumption has to be revisited. We showCancer Cell 24, 15–29, July 8, 2013 ª2013 Elsevier Inc. 25
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+-+-+-+-+-+-+-farB0274XLP
GSK1904529A IGF-1R/IR 1.30 0.61 1.21 0.51 1.07 0.60 0.93 0.64 1.05 0.61 1.14 0.84 1.10 0.39
Sunitinib PDGFRA, KIT 1.17 0.42 1.10 0.39 0.94 0.49 0.93 0.57 1.12 0.72 1.32 0.79 1.01 0.25
Imatinib Abl, KIT, PDGFR 1.37 0.60 1.21 0.55 1.13 0.62 1.04 0.63 1.24 0.77 1.33 0.86 0.99 0.33
TAE684 ALK 0.76 0.25 0.59 0.22 1.41 0.28 0.90 0.53 0.95 0.47 1.29 0.77 1.20 0.04
PF2341066 MET, ALK 1.30 0.46 1.02 0.45 1.03 0.72 0.99 0.66 1.14 0.70 1.18 0.71 1.40 0.34
XAV 939 TNKS1/2 (Wnt) 1.40 0.48 1.26 0.47 1.26 0.50 0.98 0.67 1.12 0.69 1.16 0.84 1.30 0.27
Gefitinib 0.2 M EGFR 0.86 0.22 0.73 0.21 1.45 0.38 0.96 0.55 1.13 0.53 1.09 0.68 1.10 0.26
Gefitinib 0.5 M EGFR 1.31 0.34 1.05 0.28 0.95 0.28 0.95 0.63 1.08 0.56 1.11 0.65 0.79 0.28
BIBW 2992 EGFR, ERBB2 1.02 0.29 0.94 0.29 0.86 0.27 0.90 0.63 0.94 0.51 0.99 0.52 0.80 0.19
SAHA (Vorinostat) HDAC I/II 1.26 0.64 1.21 0.46 1.06 0.47 0.91 0.66 0.96 0.67 1.12 0.81 0.94 0.45
AZD2281 (Olaparib) PARP1/2 1.19 0.51 1.09 0.40 0.96 0.42 0.94 0.68 1.04 0.66 1.10 0.65 0.79 0.23
ABT-263 Bcl-2, Bcl-xl 1.32 0.27 1.06 0.27 1.53 0.72 0.96 0.71 0.94 0.37 1.19 1.01 1.80 0.03
Lenalidomide TNF alpha 1.33 0.60 1.10 0.51 0.98 0.47 0.85 0.63 0.97 0.66 1.14 0.57 1.01 0.30
Axitinib PDGFR, KIT, VEGFR 1.22 0.51 1.09 0.45 1.15 0.52 1.00 0.65 1.02 0.64 1.11 0.72 0.91 0.27
CEP-701 (Lestaurtinib)JAK2, FLT3 0.87 0.40 0.79 0.32 1.06 0.36 0.69 0.33 0.84 0.49 0.74 0.45 1.14 0.26
CHIR-99021 GSK-3 1.20 0.63 1.08 0.52 1.69 0.34 0.89 0.75 1.11 0.55 1.02 0.80 0.83 0.27
72.072.148.090.196.032.137.000.114.041.125.045.005.082.183p207-XV
KU-55933 ATM 1.09 0.46 1.18 0.45 0.86 0.48 0.99 0.69 0.97 0.64 0.98 0.73 0.86 0.34
Elesclomol Hsp70 inducer 1.06 0.52 1.06 0.51 0.82 0.17 0.89 0.69 1.01 0.64 0.71 0.41 0.68 0.25
GDC-0449 SMO (Hedgehog) 1.16 0.59 1.15 0.61 0.93 0.52 0.96 0.64 1.02 0.61 1.04 0.63 0.71 0.26
SL 0101-1 Rsk, AURKB, PIM3 1.06 0.58 1.01 0.56 0.86 0.51 1.03 0.67 1.09 0.58 1.06 0.52 0.83 0.27
BIRB 0796 p38, JNK2 1.26 0.50 1.10 0.54 0.85 0.38 0.94 0.57 1.16 0.65 1.08 0.56 0.70 0.23
JNK inhibitor VIII JNK 1/2/3 1.19 0.64 1.14 0.62 0.92 0.38 0.96 0.71 1.08 0.62 0.97 0.73 0.82 0.38
PD173074 FGFR 1.16 0.51 1.06 0.49 0.91 0.51 0.97 0.67 1.06 0.67 1.03 0.80 0.75 0.28
ZM447439 AURK B 1.11 0.43 0.96 0.40 1.08 0.48 0.96 0.75 1.10 0.60 1.09 0.87 0.92 0.32
GW843682X (AN-13) PLK1 1.02 0.50 1.03 0.44 0.74 0.46 0.87 0.63 1.05 0.62 1.02 0.57 0.83 0.21
SB590885 RAF 0.67 0.55 0.68 0.55 0.89 0.40 0.77 0.59 1.11 0.72 0.90 0.67 0.13 0.08
WO2009093972 PI3K beta 1.03 0.34 1.04 0.35 1.05 0.45 0.91 0.59 1.01 0.58 0.98 0.66 0.68 0.25
BMS-708163 Gamma-secretase 1.04 0.59 1.00 0.61 1.08 0.28 0.92 0.59 0.94 0.54 1.01 0.56 0.81 0.24
Obatoclax mesylate Mcl-1 0.81 0.30 0.81 0.37 0.98 0.19 0.85 0.59 0.88 0.53 0.94 0.49 0.86 0.14
Nutlin-3 MDM2 1.01 0.48 0.95 0.39 0.93 0.46 0.95 0.64 1.02 0.57 0.87 0.46 0.82 0.21
Embelin XIAP 1.04 0.43 0.94 0.41 0.87 0.44 0.89 0.59 0.91 0.59 1.03 0.62 0.78 0.21
Rapamycin mTOR 0.53 0.18 0.40 0.17 0.83 0.33 0.88 0.46 0.77 0.42 0.64 0.28 0.97 0.16
BMS-536924 IGF-1R 0.75 0.25 0.75 0.23 1.16 0.18 0.82 0.39 0.71 0.30 0.99 0.56 0.91 0.01
SB-505124 TGFβR-I (ALK5) 1.10 0.70 1.11 0.79 0.81 0.35 0.85 0.58 0.95 0.58 0.95 0.69 0.70 0.21
GSK 269962A ROCK1/2 1.02 0.65 1.01 0.56 0.93 0.47 0.84 0.47 0.48 0.11 1.06 0.66 0.93 0.32
17-AAG Hsp90 1.13 0.48 0.53 0.37 0.10 0.04 0.95 0.76 0.97 0.58 1.01 0.70 0.09 0.03
VX-680 (MK-0457) AURKs, ABL, FLT3 0.49 0.26 0.43 0.24 1.23 0.26 0.84 0.51 0.52 0.14 0.34 0.14 0.20 0.00
Dasatanib SRC, BCR-ABL 0.53 0.12 0.45 0.11 1.25 0.17 0.95 0.55 1.17 0.58 1.08 0.62 1.22 0.16
AZD 7762 Chk 1/2 0.11 0.08 0.09 0.07 0.29 0.10 0.86 0.69 0.07 0.03 0.88 0.54 0.91 0.13
PD-0332991 CDK 4/6 0.57 0.22 0.60 0.21 1.18 0.12 0.68 0.35 0.62 0.25 0.72 0.36 0.62 0.11
BX 795 PDK1, TBK1, IKKe 0.32 0.20 0.33 0.20 0.89 0.79 0.89 0.61 0.91 0.49 0.92 0.50 0.90 0.27
NVP-BEZ235 PI3K/mTOR 0.49 0.18 0.47 0.17 0.90 0.45 0.86 0.44 0.82 0.45 0.66 0.35 0.78 0.15
MK-2206 AKT 0.19 0.10 0.21 0.09 1.21 0.35 0.94 0.49 0.58 0.29 0.86 0.46 1.17 0.12
AZD8055 mTORC1/2 0.25 0.08 0.24 0.08 1.17 0.29 0.57 0.30 0.31 0.18 0.77 0.35 1.10 0.04
GDC0941 PI3K (a,b,d) 0.04 0.00 0.05 0.00 1.02 0.07 0.76 0.33 0.50 0.15 0.55 0.21 1.10 0.02
AZD6244 MEK 1/2 0.29 0.18 0.29 0.17 0.31 0.07 0.56 0.24 0.44 0.21 0.71 0.48 0.09 0.01
AZD6244 + MK-2206 MEK1/2 + AKT 0.09 0.05 0.10 0.06 0.19 0.04 0.44 0.16 0.21 0.09 0.49 0.32 0.01 0.00
PD0325901 MEK 1/2 0.13 0.06 0.11 0.10 0.13 0.03 0.26 0.21 0.16 0.08 0.46 0.34 0.00 0.00
44.099.041.169.067.000.139.030.169.099.008.099.067.039.0OSMD
11.180.101.180.169.050.120.150.189.070.190.160.131.140.1OSMD
10.178.089.059.040.139.089.079.088.099.099.099.099.049.0OSMD
58.049.019.000.169.059.059.049.089.009.039.049.039.040.1OSMD
79.021.140.110.130.170.160.110.140.150.120.120.189.040.1OSMD
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Figure 8. Progression Model of BrafV637E-
Induced Intestinal Cancer Development
Braf mutation induces sustained hyperplasia.
MSI-H develops in 40% of cases and is observed
in all subsequent stages of tumorigenesis,
suggesting its early development. Dysplasia pro-
gression is driven by stage-specific Wnt pathway
activation and Braf/Mek/Erk signaling intensifica-
tion. Selective pressure for inactivation of the
p16/Rb and Arf/p53 pathways develops late dur-
ing tumorigenesis and promotes invasion and
metastasis but does not accelerate early adenoma
initiation. This late-stage specificity results from
the inability of low-dose Mapk signaling to activate
these tumor suppressors at early stages of
tumorigenesis.
Cancer Cell
Braf-Induced Intestinal Tumorigenesisthat p53 mutations accumulate spontaneously in BrafV637E-
induced murine tumors and provide functional in vivo evidence
for its tumor suppressive function. These results are supported
by a recent large study, describing that nearly 30% of the 141
examined BRAF mutant human CRCs have p53 mutations
(Bond et al., 2011).
Twomain findings established the late-stage specificity of p53
tumor suppression. First, selective pressure for p53 inactivation
developed during advanced but not early tumorigenesis. Sec-
ond, experimental p53 inactivation in Vil-Cre;BrafLSL-V637E/+
mice promoted invasion and metastasis but did not affect ade-
noma initiation. Mechanistically, our studies suggest a model
in which low-level oncogenic signaling observed during early
stages of tumorigenesis can drive proliferation, but is insufficient
to substantially induce p19Arf or p16Ink4a. It is only during
dysplasia progression when oncogenic signaling exceeds crit-
ical thresholds that these tumor suppressors are substantially
activated. Dose-dependent effects of oncogenes have been
recently observed in breast and lung cancer (Feldser et al.,
2010; Junttila et al., 2010; Sarkisian et al., 2007; Murphy et al.,
2008), but are in many aspects highly context-dependent.
Mapk signaling amplification in KrasG12D-driven lung cancer for
example occurs at later stages than in our intestinal cancer
model (Feldser et al., 2010; Junttila et al., 2010). Dosage effects
of oncogene activation probably reflect a mechanism to distin-
guish physiologic/regenerative from oncogenic growth factor
receptor signaling. This discrimination might be of particular
importance in the intestine, a highly proliferative organ that is
constantly exposed to infectious/toxic damage.Figure 7. Systematic Drug Screening Identifies Targets for Therapeuti
(A) In vitro growth inhibition assays (CellTiter-Blue assay) using a murine and five h
for 6 days. Error bars, SEM; n = 2.
(B) Systematic drug sensitivity screens using 50 compounds. For each cell line,
PLX4720 (right columns). Cell viability was determined after 6 days of treatment u
of two determinations with similar results is shown.
(C) Long-term colony-forming assays. Cells were treated with PLX4720 (0.5 mM),
PD0325901 (0.002 mM) as single agents or their combination as indicated. One o
(D) TheMek inhibitor PD0325901 suppresses tumor growth in allo- and xenograft
cell lines were transplanted s.c. into Nod Scid IL12Rgnull (NSG) mice. Treatment w
with vehicle (control) or 25 mg/kg/day of PD0325901 for 15 days by oral gavage.
SEM; n = 4–5 mice per group.
(E) Combinatorial Braf/PI3K inhibition suppresses tumor growth of MouseT1 and
vehicle (control) or PLX4720 50 mg/kg/day once daily plus GDC09041 75 mg/kg/
0.01; t test.
See also Figure S6 and Table S7.BRAF mutations affect a large variety of cancers; however,
response rates to Braf inhibitors differ significantly, ranging
from 80% in melanoma to less than 10% in BRAF mutant CRC
(Prahallad et al., 2012). The results of our systematic drug
screens in BRAF mutant CRC have several implications. First,
we demonstrate comparable responses of murine and human
BRAF mutant tumors to targeted therapeutics, supporting the
usefulness of our models for preclinical research. Second, we
identified and validated compounds in vivo that overcome resis-
tance to Braf-inhibitor therapy in selected cell lines or across the
whole panel, e.g., Mek and combinatorial Braf/PI3K inhibition.
Various Mek, PI3K, and BRAF-inhibitors are in late-stage clinical
development (Rusconi et al., 2012; Chappell et al., 2011; Flaherty
et al., 2012a, 2012b), and our results provide a rationale for their
clinical evaluation in BRAF mutant CRCs. Third, individual cell
lines showed sensitivity to multiple drugs, which often had
different targets, suggesting therapeutic options for second- or
third-line treatment in tumors that developed resistance to initial
regimes. All together these studies show the power of combining
genomic information with systematic high-throughput pharma-
cologic profiling to guide rational therapeutic strategies for
specific cancer subentities.
EXPERIMENTAL PROCEDURES
Generation of a Conditional BrafV637E Allele
Themouse Braf p.V637Emissense mutant protein is the murine counterpart of
the human BRAF p.V600E oncogenic variant. V637 is encoded in Braf exon 18
(CCDS39463.1), the murine ortholog to human BRAF exon 15. Details of allele
construction and genotyping protocols are described in the Supplementalc Intervention in BrafV637E-Induced Murine and Human Cancers
uman BRAFmutant intestinal cancer cell lines. Drug treatment was performed
drugs were used as single agents (left columns) or in combination with 0.5 mM
sing CellTiter-Blue. Results are shown relative to DMSO control treatment. One
Gefitinib (0.5 mM), the PI3K inhibitor GDC0941 (0.5 mM), and the Mek inhibitor
f two determinations with similar results is shown.
models. The Brafmutant murine (MouseT1) and human (HT-29 and COLO-205)
as started when tumors were palpable (day 1). Animals were treated once daily
*p < 0.05; **p < 0.01; ***p < 0.001; Mann-Whitney rank sum or t test; Error bars,
COLO-205 cells, transplanted s.c. into NSG mice. Animals were treated with
day twice daily by oral gavage. Error bars, SEM; n = 3–5 mice per group; **p <
Cancer Cell 24, 15–29, July 8, 2013 ª2013 Elsevier Inc. 27
Cancer Cell
Braf-Induced Intestinal TumorigenesisExperimental Procedures. Animal protocols were approved by the Home
Office (UK) and specified in the Home Office Project License.
Quantitative PCR
qRT-PCR was performed as described earlier (Rad et al., 2006). Primer/probe
sequences are available upon request.
Methylation Analysis
Methylation-specific PCR was performed upon treatment of DNA with sodium
bisulphite. Pyrosequencing reactions and methylation quantification were
performed in a PyroMark Q24 System version 2.0.6 (QIAGEN). For detailed
description, see the Supplemental Experimental Procedures.
Sequencing
The coding exons from target genes were enriched either by PCR or via pull
down using Agilent SureSelect Mouse Exon Kit. Sequencing was performed
using next-generation technologies: Roche 454 GS-FLX (for PCR-amplified
p53 exons) or Illumina HiSeq2000 (for whole-exome sequencing). Calling
algorithms will be published elsewhere and are only briefly summarized in
the Supplemental Experimental Procedures.
Histochemistry, Immunohistochemistry, TUNEL Assay, andWestern
Blotting
Standard techniques were used and are described together with information
about antibodies in the Supplemental Experimental Procedures.
Comparative Genomic Hybridization
CGH array was executed using Agilent 244K mouse whole genome arrays as
described previously (Rad et al., 2010).
MSI Analysis
Microsatellite instability (MSI) was examined using eight microsatellite repeat
markers. For details of the method, references, and classification see the
Supplemental Experimental Procedures.
Drug Sensitivity Assays
Drug sensitivity assays were described earlier (Garnett et al., 2012). Specific
details used in this study are described in the Supplemental Experimental
Procedures.
Tumor Implantation and Treatment of Mice
Animals were implanted subcutaneously or orthotopically with 13 107 cancer
cells suspended in culture medium including 50% Matrigel (Beckton Dickin-
son). Treatment was started when tumors were palpable. Animals were treated
once daily with vehicle or 25 mg/kg/day of PD0325901 or a combination of
PLX4720 50 mg/kg/day once daily plus GDC09041 75mg/kg/day twice daily
by oral gavage for up to 15 days, as indicated in the figure legends. Treatment
of endogenous tumors in Vil-Cre;BrafLSL-V637E/+ mice was performed for
5 days.
ACCESSION NUMBERS
The EBI European Nucleotide Archive accession number for data presented in
this study is PRJEB3418.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.05.014.
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